Rina-S + Paclitaxel + Topotecan + Pegylated liposomal doxorubicin (PLD) + Gemcitabine
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum-resistant Ovarian Cancer
Conditions
Platinum-resistant Ovarian Cancer
Trial Timeline
Feb 7, 2025 → May 23, 2028
NCT ID
NCT06619236About Rina-S + Paclitaxel + Topotecan + Pegylated liposomal doxorubicin (PLD) + Gemcitabine
Rina-S + Paclitaxel + Topotecan + Pegylated liposomal doxorubicin (PLD) + Gemcitabine is a phase 3 stage product being developed by Genmab for Platinum-resistant Ovarian Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06619236. Target conditions include Platinum-resistant Ovarian Cancer.
What happened to similar drugs?
0 of 2 similar drugs in Platinum-resistant Ovarian Cancer were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
17
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06619236 | Phase 3 | Active |
Competing Products
16 competing products in Platinum-resistant Ovarian Cancer